Lin X, et al. - Experts sought to inspect the utility of MDM2 and p16 along with HMB45 and Melan-A immunohistochemical analysis in distinguishing angiomyolipoma (AML) from well-differentiated liposarcoma (WDLS)/dedifferentiated liposarcoma (DDLS) or lipoma. Data revealed that MDM2 expression solely could not exclude the diagnosis of AML or lipoma. Additionally, p16 alone was not beneficial for distinguishing AML and conventional lipoma from WDLS/DDLS. Nevertheless, an immunohistochemical battery including HMB45, Melan-A, MDM2 and p16 along with morphology aided in distinguishing AML from WDLS/DDLS or lipoma. Data recommended fluorescence in situ hybridization for MDM2 for equivocal cases.